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Hypertension and Cardiovascular Disease: Contributions of
the Framingham Heart Study
Stanley S. Franklin, Nathan D. Wong
Irvine, CA, USASUMMARY
This is a historical review of the contribution of the Framingham Heart Study to our understanding of the
epidemiology of blood pressure (BP) and cardiovascular disease (CVD). Framingham investigators initially
explored the epidemiological relationship of various BP components to coronary heart disease in men and
women and how this risk is further modiﬁed by age, that is, how diastolic blood pressure (DBP) is the stronger
predictor of coronary heart disease risk in young people versus systolic blood pressure (SBP) in middle-aged
and elderly people. Framingham investigators then examined the natural history of various BP components
over a 30-year follow-up in normotensive and untreated hypertensive individuals and showed how this
provides hemodynamic insights into the importance of pulse pressure as a marker of large artery stiffness in
middle-aged and elderly people. Importantly, pulse pressure was also found to be superior to SBP or DBP as
a predictor of coronary heart disease in a middle-aged and elderly Framingham population. Lastly, dual models
of SBP with DBP and pulse pressure with mean arterial pressure were superior to single BP component models
for predicting CVD events; thus, increases in both peripheral vascular resistance and central large artery stiffness
contribute to CVD in varying proportions depending on age. Furthermore, the Framingham Heart Study
provided evidence that DBP <70 mm Hg with SBP 120 mm Hg was associated with a CVD risk equivalent to
approximately 20 mm Hg of additional elevation in SBP, thus further supporting the importance of large artery
stiffness as a CVD risk factor in elderly people. These original Framingham studies have contributed greatly to
BP risk classiﬁcation tables for the “Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure” and for the European Society for Hypertension. Moreover,
Framingham originally brought attention to hypertension, which is now the leading cause of mortality globally.From the Heart Disease
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Open access under CC BY-NC-ND license.In 1949, Charles Friedberg [1] noted that there was
“a lack of correlation between the severity and duration and
hypertension and the development of cardiac complica-
tions.” In 1970, Karl Engleman and Eugene Braunwald [2]
stated, “systolic hypertension in the presence of normal or
reduced diastolic blood pressure is rarely considered to be
responsible for organ damage, but usually reﬂects other
pathologic processes.” Thus, the medical conventional
wisdom in the second half of the 20th century was
frequently in error in overlooking hypertension in general
and systolic hypertension in particular as important risk
factors for cardiovascular disease (CVD).
In 1959, an original article by Kagan et al. [3] from the
Framingham Heart Study noted that “the relation of
hypertension and atherosclerosis was still poorly under-
stood.” Importantly, the contribution of more than a half
century of work from Framingham Heart Study investiga-
tors has provided signiﬁcant insight into the epidemiology
and CVD outcomes associated with hypertension and on
the relation of systolic blood pressure (SBP), diastolic blood
pressure (DBP), pulse pressure (PP), and mean arterial
pressure (MAP) with CVD outcomes. This review describes
the methodology and ﬁndings related to 5 key publications
about the epidemiology of BP and its clinical signiﬁcance:
1) BP and its relation to CHD [3]; 2) SBP versus DBP andGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57risk of CHD [4]; 3) hemodynamic patterns of age-related
changes in BP [5]; 4) PP and risk of CHD [6]; and 5) the
role of single versus combined BP components in relation
to CVD risk [7].
BLOOD PRESSURE AND ITS RELATION TO
CORONARY HEART DISEASE
Kagan et al. [3], in 1959, ﬁrst described the relation of the
distribution of BP in Framingham and the relation of BP to
the development of coronary heart disease (CHD) over an
initial 6-year follow-up period. Between 1949 and 1952,
4,469 participants of 6,510 selected agreed to participate
and be examined. A detailed medical history and physical
examination was included, and BP were taken on both
arms in the seated position. Height, weight, vital capacity,
and a 12-lead electrocardiogram and postero-anterior chest
ﬁlm in addition to a urinalysis and blood analysis for
hemoglobin, glucose, uric acid, and cholesterol were done.
A second physician examined each subject performing
a second left arm BP as well, but analyses in this ﬁrst report
were based on the ﬁrst examiner’s left arm BP.
Initial ﬁndings regarding the description of BP
measures noted by the investigators were: 1) the choice of
left versus right arm for taking BP did not differ, and
differences were random to a similar degree to what49
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50measurements on the same arm would exhibit; and 2)
there was a digit preference for recording even numbers for
BP, with 0 being the most commonly measured digit.
Importantly, Framingham noted that both mean SBP and
DBP rose steadily with age in both men and women;
although, amongmen, there was no further increase after the
age of 50 years in DBP. Interestingly, there was a crossover
between men and women in SBP in the 45 to 49 years age
group, after which levels were higher in women and a similar
crossover in DBP at the next highest (50 to 54 years) age
group. Finally, the investigators observed a “white coat” BP
effect in subjects attending early biennial visits, noting that
there was a downward trend both in SBP that averaged 136.5
mmHg at the ﬁrst exam, but decreased to 131.4 by the third
exam, and DBP decreasing from 85.4 mm Hg to 81.6 mm
Hg, respectively. They attributed this as “due to the famil-
iarity with the examination procedure and a decreasing
psychogenic reaction to the examination.”
Realizing that the increasing BP with age might be
related to the greater prevalence of CVD, the Framingham
investigators also examined the age-BP relationship among
so-called normal persons, which excluded any with known
evidence of CVD, cardiac enlargement by x-ray, or signif-
icant electrocardiographic abnormalities. They found the
upward trend of BP persisted as well in this “normal”
group. Further analysis also characterized BP levels
according to different diagnostic categories of CHD and
found signiﬁcantly elevated BP to be present in particular
among those with angina pectoris.
Of particular interest, Framingham was among the
ﬁrst to describe the prevalence of normal, borderline, and
elevated (hypertension) BP according to what were newly
recommended criteria by the Subcommittee on Blood
Pressure of the Conference on Longitudinal Cardiovas-
cular Studies held in June 1957. At that time, a normal
BP was deﬁned as readings of <140 mm Hg systolic and
<90 mm Hg diastolic by 2 examiners and deﬁnite
hypertension as readings of a systolic of 160 mm Hg orTABLE 1. Six-year rate of coronary heart disease events (per 1,00
ventricular hypertrophy and/or cardiac enlargement (n ¼ 1,246)
All
Deﬁnite hypertensive heart disease
Deﬁnite hypertension
Possible hypertensive heart disease
Borderline hypertension
Normotension
LVH (deﬁnite or possible) or cardiac enlargement by x-ray
LVH (Deﬁnite or Possible) by ECG
ECG, electrocardiograph; LVH, left ventricular hypertrophy.
Adapted, with permission, from Kagan et al. [3].diastolic of 95 mm Hg, with readings in between
deﬁned as possible high BP. In addition, this group
deﬁned a subgroup of systolic hypertension based on
elevated SBP but normal DBP at these cut points. Among
the 4,469 persons evaluated, 801 (17.9%) had deﬁnite
hypertension, 1,577 (35.3%) borderline hypertension,
and 2,091 (46.8%) were normotensive.
In the same paper [3], the investigators also went on to
describe the close relation between cardiac enlargement
and BP. Whereas cardiac enlargement was found at all BP
levels, there were also persons with normal-sized hearts no
matter how high their BP was, indicating individual vari-
ability in the susceptibility to cardiac enlargement at any BP
levels. They found that electrocardiographic evidence of
left ventricular hypertrophy was a more deﬁnite indicator
of hypertension than was cardiac enlargement by x-ray.
With regard to follow-up for CHD events, this paper
describes the total cohort of 5,209 subjects with 6-year
follow-up, of which only 4 were lost to follow-up. Over
these initial 6 years, there were 186 new CHD events,
including 125 in men and 61 in women, of which 71 were
deﬁnite myocardial infarction. Incident CHD was approxi-
mately twice as great in men as in women. The investigators
noted a rate of new CHD (per 1,000) that was highest in
those with deﬁnite and probably hypertensive heart disease,
intermediate in those with hypertension, and lowest in those
with borderline and normal BP among bothmen andwomen
(Table 1). CHD rates were also highest in those with left
ventricular hypertrophy by electrocardiogram as opposed to
left ventricular hypertrophy or generalized cardiac enlarge-
ment by x-ray. The investigators also described the relation
of DBP to CHD events, stratiﬁed by cholesterol levels, noting
a more dramatic rise in CHD event risk with DBP among
those with higher versus lower cholesterol levels (Fig. 1).
SYSTOLIC VERSUS DIASTOLIC BP AND RISK OF CHD
Critical to the further development of BP as a risk factor for
CHD was deciphering the relative contributions of SBP and0) according to blood pressure category and presence of left
Men Ages
29e44 Years
Men Ages
45e62 Years
Women Ages
45e62 Years
24.9 90.6 44.6
62.5 182.9 101.4
28.8 125.8 64.7
50.8 141.2 51.9
24.2 93.8 38.6
22.0 40.9 10.2
32.3 118.4 60.0
64.5 285.7 106.4
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FIGURE 1. Relation of diastolic blood pressure stratiﬁed
by total cholesterol level to 6-year incidence of coronary
heart disease events in the Framingham Heart Study.
Reprinted, with permission, from Kagan et al. [3].
gREVIEWjDBP to predicting risk. By 1971, Kannel et al. [4] felt that it
“is generally conceded that elevated levels of BP play an
important role in the pathogenesis of atherothrombotic
disease, the most prominent cause of mortality in the
United States”; however, they noted that “the relative
importance of various indices of BP such as PP, MAP,
lability and SBP versus DBP in the pathogenesis of
cardiovascular sequelae of hypertension have yet to be
adequately explored.” These investigators felt that with 14
years of follow-up in Framingham and with the 492
accumulated cases of CHD that it was now possible to
examine some of these issues.
Of particular interest, because SBP and DBP were highly
correlated, it was necessary to do a “multivariate analysis of
each as a discriminator of potential coronary heart disease.”
Framingham is among the ﬁrst studies to recognize the role
of examining “independent contributions” of multiple, often
correlated variables and, hence, has championed the devel-
opment of the concept of multivariable analyses used nearly
universally in epidemiologic research today. In this 1971
study [4], the investigators determined for each age-sex
group the standardized mean differences in BP (the mean
BP of subjects withCHDminus themeanBP of thosewithout
disease over the standard deviation of the population)
between those where CHD did and did not develop,
providing a directmethod of comparing the power of these 2
measures. They then constructed a discriminatory function
to be able to compare the contributions of each variable
separately and then together.
Figure 2 shows descriptively the average annual inci-
dence of CHD over 14 years according to the level of SBP
and DBP. Particularly in older men, there is a clearly
stronger gradient of risk associated with increasing SBP as
opposed to DBP. But because the investigators pointed outGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57that there was no critical level for SBP or DBP identiﬁed,
they felt it was necessary to look at the net contribution to
risk from the actual level of each of the pressures in further
analyses, and in particular for comparing SBP versus DBP,
to determine the standardized slopes of the incidence of
CHD. In doing this analysis, they found that the stan-
dardized slopes for women and or men ages 45 years and
over were greater for SBP than for DBP. For example, in
those ages 55 to 64 years, the standardized slope of annual
incidence of CHD in men was 0.54 for SBP and 0.41 for
DBP and for women was 0.69 and 0.41 (all p < 0.05).
Furthermore, the standardized mean difference of SBP and
DBP is another way of demonstrating discriminatory power
of these 2 components of BP, and these values were indeed
also greater for most age groups in both men and women
for SBP as compared to DBP (overall weighted average in
men 0.41 for SBP and 0.28 for DBP and for women 0.68
and 0.39). This indicated that the association with CHD
was stronger for SBP than for DBP.
This Framingham Heart Study [4] was the ﬁrst to
dispel the notion of DBP being the key BP component
associated with hypertensive risk for the majority of
middle-aged and elderly subjects that had predominantly
systolic hypertension. In contrast, in the pre-
antihypertensive treatment era, very high DBP was
commonly associated with “malignant” or “accelerated”
hypertension—frequently resulting in a rapid, fatal course;
however, it was noted that invariably these persons had an
accompanying very high level of SBP. Importantly, this
Framingham study showed a declining relative importance
of DBP and increasing importance of SBP with age; in
contrast, only in those under age 45 years was DBP more
important than SBP—with the exception of the ominous,
malignant/accelerated forms of hypertension, which were
very rare in the Framingham cohort. The investigators
concluded, “Neither the systolic and diastolic pressure
measurements in combination nor the pulse pressure and
the mean arterial pressure measurements alone discrimi-
nated better than the systolic measurement alone.” Thus,
the current practice of assessing the importance of BP at all
ages largely based on DBP had to be re-examined. It should
be noted historically, however, that it took an additional 20
years (1991) with the publication of the SHEP (Systolic
Hypertension in the Elderly Program)—the ﬁrst random-
ized controlled trial in an elderly population with isolated
systolic hypertension—to prove the value of antihyper-
tensive therapy in reducing cardiovascular morbidity and
mortality in persons with isolated systolic hypertension.HEMODYNAMIC PATTERNS OF AGE-RELATED
CHANGES IN BP
In 1997, Franklin et al. [5] had the unique opportunity to
study age-related changes in SBP, DBP, PP, and MAP with
biannual examinations over a 30-year follow-up period in
both normotensive and untreated hypertensive subjects
from the original Framingham Heart Study, which51
FIGURE 2. Average annual incidence of coronary heart disease, 14-year follow-up, according to systolic and diastolic
blood pressure, Framingham Heart Study, men and women ages 35 to 64 years. Reprinted, with permission, from
Kannel et al. [4].
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52provided new insight into the importance of PP as
a surrogate marker of large artery stiffness with aging. They
divided 2,036 participants without CVD or who were not
on antihypertensive therapy into 4 SBP groups (Fig. 3).
Regression of BP versus age produced slope and curvature
estimates for the various BP components: SBP (linear rise),
DBP (quadratic pattern), MAP (late asymptote), and PP
(late linear rise). After 50 years of age, SBP increased
disproportionately to DBP, and after 60 years of age, DBP
fell, resulting in a further widening of PP. Age-related linear
increases in SBP, PP, and MAP, as well as the curvilinear
rise and fall in DBP, were greatest for subjects with the
highest baseline SBP.
The Framingham ﬁndings also supported the concept
of an interaction between aging and hypertension in the
progressive fall in DBP and rise in SBP; the changing
pattern with aging suggested 3 hemodynamic phases.
Under age 50 years, the progressive rise in DBP and SBP
suggested the predominance of increased vascular resis-
tance. The constancy of DBP for those in their 50s, together
with the asymptotic leveling of MAP and increased slope of
PP, suggested increased vascular resistance and large artery
stiffness were both increasing in a parallel manner. The fall
in DBP during later ages signaled preponderance of largeartery stiffness as the cause of further rise in SBP and,
hence, dramatic widening of PP in the elderly. We
hypothesized that the age-related stiffening of the aorta was
associated with a decreased capacity of the elastic reservoir
and, hence, a greater peripheral runoff of stroke volume
during systole. Thus, with less blood remaining in the aorta
at the beginning of diastole, and with diminished elastic
recoil, DBP decreased with increased steepness of diastolic
decay.
The “healthy” subjects with a mean baseline BP of 111/
70 mm Hg (Fig. 3, group 1) had no rise in PP and only
a minimal increase in MAP from age 30 to mid-50 years.
Nevertheless, these normotensive subjects showed
a signiﬁcant rise in PP and fall in DBP after age 55 years,
presumably caused by an increase in large artery stiffness
secondary to aging. In contrast, hypertensive subjects with
baseline mean BP of 130/84 mm Hg (Fig. 3, group 4)
showed a shallow rise in PP from age 30 years onward,
followed by a steeper widening of PP and a steeper fall in
DBP after age 55 years than was observed in group 1
subjects. These ﬁndings suggest a linkage between hyper-
tension left untreated and the subsequent acceleration of
large artery stiffness. Although increased peripheral
vascular resistance may initiate essential hypertension,GLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57
FIGURE 3. Arterial pressure components by age: group averaged data for all subjects and with deaths, myocardial
infarction (MI), and coronary heart failure (CHF) excluded. Averaged blood pressure levels from all available data
from each subject within 5-year age intervals (30 to 34 years through 80 to 84 years) by systolic blood pressure (SBP)
groupings 1 through 4. Thick lines represent entire study cohort (2,036 subjects); thin line represents study cohort
with deaths and nonfatal MI or CHF excluded (1,353 subjects). Reprinted, with permission, from Franklin et al. [5].
gREVIEWjacceleration of large artery stiffness is the driving force
leading to steeper rise in SBP after age 55 years in the
hypertensive groups 3 and 4 as compared to the normo-
tensive groups 1 and 2 (Fig. 3).
The clinical implications that can be derived from this
study are that, after the sixth decade of life: 1) increasing PP
and decreasing DBP are surrogate measurements for large
artery stiffness; 2) large artery stiffness rather than vascular
resistance becomes the dominant hemodynamic factor in
both normotensive and hypertensive subjects; 3) hyper-
tension, left untreated, may accelerate the rate of devel-
opment of large artery stiffness, which can perpetuate
a viscous cycle of worsening hypertension and further
increases in large artery stiffness; and 4) these factors may
play a role in risk stratiﬁcation of elderly people and
decision making in the selection of treatment modalities.IS PP USEFUL IN PREDICTING RISK FOR CHD?
When Kannel et al. [4], in 1971, showed that SBP was
superior to DBP as a predictor of CHD in middle-aged and
older persons, they concluded that PP added nothing to
the discriminating power of SBP; in part, this conclusionGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57rested on the close correlation between SBP and PP as
predictors of CHD. In 1999, when Franklin et al. [6]
reexamined this question, using an updated Framingham
population, Cox regression analysis was available to allow
adjustment for various covariates that might confound
results. They studied 1,924 men and women, ages 50 to 79
years at baseline, with no clinical evidence of CHD, not on
antihypertensive drug treatment, and with a 20-year
follow-up for incident fatal and nonfatal CHD. Cox
regression was adjusted for age, sex, body mass index,
cigarettes smoked per day, glucose intolerance, and total
cholesterol/high-density lipoprotein ratio. Comparison of
dual BP component models (Table 2) showed that the
combination of DBP and SBP (model 1) showed a modest
incremental contribution to risk as compared to SBP alone,
whereas a model of the combination of DBP and PP (model
2) or a third model of SBP and PP (model not shown)
showed no additional increased risk as compared to PP
alone. Thus, when considered jointly in this older age
group, SBP was positively associated with risk and DBP
was inversely related to risk. Furthermore, when the joint
inﬂuence of SBP and PP on CHD risk was plotted at 4
different SBP groupings (110, 130, 150, and 170 mm Hg)53
TABLE 2. BP and CHD risk dual BP component models
Chi-Square Hazard Ratio p Value
Model 1
SBP 35.6 1.22 (1.15e1.30) <0.001
DBP 5.2 0.86 (0.75e0.98) <0.05
Model 2
DBP 0.7 1.04 (0.94e1.16) NS
PP 35.6 1.22 (1.15e1.30) <0.001
Hazards associated with 10 mm Hg increment in the corresponding
BP component. Likelihood ratio statistics are for each BP variable
added to a model that contains 1 other BP variable. Associated with
a 1-SD increment in the corresponding BP component. Adjusted for
age, sex, cigarettes smoked per day, electrocardiograph-detected
left ventricular hypertrophy, body mass index, glucose intolerance,
and total and high-density lipoprotein cholesterol.
BP, blood pressure; CHD, coronary heart disease; DBP, diastolic
blood pressure; NS, not signiﬁcant; PP, pulse pressure; SBP, systolic
blood pressure.
Reprinted, with permission, from Franklin et al. [6].
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54with SBP of 130 mm Hg set to a reference value of 1.0
(Fig. 4), one could examine the inﬂuence of risk over
a wider range of PP and DBP values. For any given level of
SBP 130 mm Hg, subjects with the higher PP (i.e., the
lower the DBP) had a considerable increased CHD risk.
Indeed, there was a far greater increase in CHD risk with
increments in PP without a change in SBP than with
increments in SBP without a change in PP.FIGURE 4. Joint inﬂuences of systolic bloodpressure (SBP), an
CHDheart rates (HR)were determined from level of PPwithin
of 130 mm Hg and PP of 50 mm Hg and are plotted for SBP
estimates were adjusted for age, sex, body mass index, ci
cholesterol. Reprinted, with permission, from Franklin et al. [From these ﬁndings, we can hypothesize that CHD
risk is more related to the pulsatile stress caused by large
artery stiffness during systole than to the steady-state stress
due to small-vessel resistance during diastole. Moreover,
this concept also explains the paradox of CHD risk being
directly related to DBP when considered alone and
inversely related to DBP when SBP and DBP were jointly
entered in the model. Considered alone, DBP is a measure
of vascular resistance. In individuals <50 years of age,
elevation of SBP and DBP are nearly concordant, strongly
supporting the major inﬂuence of vascular resistance in
young adults. In contrast, in middle-aged and elderly
people, PP, which is an indicator of large-artery stiffness,
becomes the predominant factor predicting CHD risk.
These ﬁndings suggest that those older subjects with
elevated SBP and discordantly low DBP values have by far
the greatest CHD risk.
The clinical implications from this study are that in
individuals with identical levels of elevated SBP, those
with isolated systolic hypertension are at greater risk for
CHD than are those with combined systolic-diastolic
hypertension (in the absence of malignant/accelerated
hypertension). This may have public health implications,
because isolated systolic hypertension is the most
common type of hypertension among untreated adults
>50 years of age [8]. For middle-aged and older persons,
these new ﬁndings call into question the prevailing belief
that elevations of SBP and DBP contribute equally to
CHD risk. Indeed, the age-related changes in PP suggest
an interaction between vascular aging and hypertension.dpulse pressure (PP) on coronary heart disease (CHD) risk.
SBP groups. HRwere set to a reference value of 1.0 for SBP
values of 110,130, 150, and 170 mm Hg, respectively. All
garettes smoked per day, glucose intolerance, and total
6].
GLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57
FIGURE 5. Odds for the likelihood of a cardiovascular
event with combined systolic blood pressure (SBP) and
diastolic blood pressure (DBP) categories in a 6 3 6
cross-classiﬁcation bar graph, adjusted for age, sex, total
cholesterol, smoking, body mass index, diabetes, and
secular trend. An interaction term of SBP 3 DBP
improved the model ﬁt. CI, conﬁdence intervals; CVD,
cardiovascular disease. Reprinted, with permissions, from
Franklin et al. [8].
FIGURE 6. Odds for the likelihood of a cardiovascular
eventwith combinedpulsepressure (PP) andmeanarterial
pressure (MAP) categories in a 6 3 6 cross-classiﬁcation
bar graph, adjusted for age, sex, total cholesterol,
smoking, bodymass index, diabetes, and secular trend. An
interaction term PP 3 MAP improved the model ﬁt.
Reprinted, with permission, from Franklin et al. [8].
TABLE 3. Prediction of CVD events by JNC-6 staging
JNC-6 Group
BP Limits,
mm Hg
SBP/DBP,
mm Hg OR (95% CI)
Optimal SBP <120
DBP <80
109/69 Ref. ¼ 1.0
Pre-hypertension SBP 120e139
DBP <70
127/65 2.0 (1.5e2.6)*
Stage 1 ISH SBP 140e159
DBP 70e89
147/81 2.0 (1.6e2.5)*
SBP 140e159
DBP <70
147/64 3.0 (2.1e4.3)*
Stage 2 ISH SBP 160
DBP <90
171/81 3.1 (2.4e4.1)*
Stage 2 SDH SBP 160
DBP 90e99
172/94 2.7 (2.0e3.6)*
SBP 160e179
DBP 100
168/106 3.6 (2.5e5.1)*
CI, conﬁdence intervals; CVD, cardiovascular disease; ISH, isolated
systolic hypertension; JNC-6, Sixth report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure; OR, odds ratio; SDH, systolic-systolic hyper-
tension; other abbreviations as in Table 2.
*p < 0.0001.
Adapted, with permission, from Franklin et al. [7].
gREVIEWjConsequently, increased large artery pulsatility has
become an important biomarker of CVD.
SINGLE VERSUS COMBINED BP COMPONENTS AND
RISK FOR CVD
When Kannel et al. [4], in 1971, showed that SBP was
superior to DBP as a predictor of CHD risk in middle-aged
and older persons, they concluded that the discriminating
power of DBP when added to SBP or of PP when added to
MAP was not superior to SBP alone in predicting CHD
risk; however, there remained controversy regarding which
BP component was the best predictor of CVD risk overall
and whether combined BP components were superior to
single ones. We further examined with greater statistical
power the CVD predictive value of combined BP compo-
nents versus single ones in a follow-up report [7] using
a Framingham population that consisted of the original
(n ¼ 4,700) and offspring (n ¼ 4,897) cohorts, free of
CVD events and without antihypertensive therapy over
a 50- versus previous 20-year period. We included 1,439
CVD events that consisted of myocardial infarction,
thrombotic and hemorrhagic stroke, heart failure, and
CHD and CVD deaths. Furthermore, we used pooled
logistic regression to examine 12 serial 4-year intervals
from 1952 to 2000, using a new index examination for
determining baseline BP for each 4-year cycle; this maxi-
mized person-observations (41,525 multiple person-
observations).GLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 49-57Using the combination of BP components of SBP with
DBP and PP with MAP in Figures 5 and 6, respectively,
rather than single BP components separately, improved the
ﬁt for predicting CVD risk. Introducing the interaction55
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56terms in Figures 5 and 6, respectively, further improved
the ﬁt over the main effects of the 2-component models,
indicating that the effect of 1 BP component on risk varied
accordingly to the level of the other. The same results were
obtained when BP was treated as a continuous variable.
These results conﬁrmed the superiority of combining SBP
and DBP as noted in the MRFIT (Multiple Risk Factor
Intervention Trial) [9] and extended the ﬁndings to older
adults and to women.
In the SBP and DBP model, CVD risk increased at both
the low and high extremes of DBP when combined with
increased SBP in the 2-component model. Therefore, there
was a DBP J-curve for CVD risk that was independent of
antihypertensive therapy and antecedent CVD events. The
J-curve relation to CVD risk that is associated with DBP
presumably reﬂects increased arterial stiffness as man-
ifested by a low DBP and by deﬁnition, a wide PP. It was
concluded that both 2-component models were superior to
any single BP component in predicting CVD risk because
they assessed both stiffness and resistance (afterload).
When PP, a measure of stiffness, was combined with MAP,
a measurement of resistance, one could relate the 2 major
physiologic components of hydraulic load to clinical
outcome.
In the models based on the “Sixth Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure” (JNC-6) categories
for SBP andDBP groupings (Table 3), SBP is usually superior
to DBP as a predictor of CVD risk; however, very low or very
high DBP add to the SBP risk. Indeed, a DBP <70 mm Hg
can add approximately 20 mm Hg of SBP risk, in other
words, a potential shift from pre-hypertension to stage 1
hypertension or from stage 1 to stage 2 hypertension. In
contrast, a DBP 100 mm Hg versus 90 to 99 mm Hg
added considerable increased CVD risk, despite somewhat
lower SBP values (Table 3).
The importance of PP as a risk predictor was not
emphasized in the 2003 “Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure” (JNC-7) recom-
mendations [10]. The Framingham 2009 ﬁndings support
the 2007 European Guidelines [11] for the Management of
Arterial Hypertension as a high-risk designation when
elevated SBP is associated with DBP of <60 to 70 mm Hg
and further suggest that the high-risk designation may also
apply to those individuals with pre-hypertension and DBP
<70 mm Hg. These ﬁndings may represent an important
insight to guide preventative and therapeutic care. More-
over, recent Framingham analyses by Vasan et al. [12,13]
showed that up to one-third of those classiﬁed currently
by the JNC-7 [10] as pre-hypertensive (previously normal
and high normal categories by the JNC-6) would develop
clinical hypertension in the next 4 years [12]. They also
found that pre-hypertension is associated with increased
risk of CVD events [13] and was a major impetus toward
the JNC-7 designation of the categorization of pre-
hypertension and the plea to healthcare providers toprovide lifestyle advice and modiﬁcations to prevent such
persons from developing clinical hypertension.
CLINICAL PERSPECTIVE
The ﬁrst 60 years of the population-based Framingham
Heart Study have contributed greatly to our knowledge of
the relation between various BP components and CVD
events in general and for CHD in particular. Ten years into
the study, there was enough data to show: 1) both mean
SBP and DBP rose steadily with age in both men and
women; 2) there was a crossover between men and women
in SBP in the 45 to 49 years age group, after which levels
were higher in women and a similar crossover in DBP at
the next highest (50 to 54 years) age group; 3) a “white
coat” BP effect of 5/4 mm Hg was noted during the ﬁrst 3
biennial examinations; 4) there was a correlation between
BP level and left ventricular hypertrophy by electrocar-
diogram; and 5) there was a correlation between BP level
and CHD that was stronger in men than in women.
Twenty years into the study, Kannel et al. [4], in 1971,
noted the following: 1) The relative importance of various
indices of BP such as PP, MAP, SBP, and DBP in the
prediction of CHD had not been adequately explored. 2)
Because SBP and DBP were highly correlated, it was
necessary to do a multivariate analysis of each BP
component to determine the best predictor of CHD. 3) The
standardized mean BP of subjects with and without CHD
for each age-sex grouping was determined in order to
compare the power of these 2 measures. 4) Kannel et al.
then made the seminal observation that while DBP was
a stronger predictor of CHD in young people <45 years of
age, SBP became the dominant predictor of CHD risk in
middle-aged and elderly people.
By about 50 years into the study, there was the unique
opportunity to study the natural history of both normo-
tensive and untreated hypertensive subjects over a 30-year
follow-up interval with adjustment for covariates and to
infer underlying hemodynamic mechanisms from age 30
to 84 years. It was concluded that: 1) after age 55 years of
age, SBP increased disproportionately to DBP, and after
60 years of age DBP fell, resulting in a further widening
of PP; 2) the increase in PP, in association with the late
fall in DBP after age 60 years and the continual rise in SBP,
was most consistent with large artery stiffness; 3) PP is
a marker for large-artery stiffness; and 4) large-artery
stiffness is the dominant factor in the rise of SBP from
middle age onward. It was hypothesized that elevated SBP
left untreated could accelerate arterial stiffness and thus
perpetuate a vicious cycle.
Our further report in 1999 concluded the following: 1)
When considered jointly in the older age group, SBP was
positively associated with CHD risk and DBP was inversely
related. 2) There was a far greater increase in CHD risk
with increments in PP without a change in SBP than with
increments in SBP without a change in PP. 3) Conse-
quently, PP as a surrogate measure of arterial stiffness,
emerged as the best single BP predictor of risk in this olderGLOBAL HEART, VOL. 8, NO. 1, 2013
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age group. 4) In middle-aged and elderly subjects, CHD
risk increased with lower DBP at any level of SBP 120
mm Hg, suggesting that wide PP was an important
component of risk. 5) CHD events are more related to the
pulsatile stress of large artery stiffness during systole than
steady-state stress of resistance during diastole.
Lastly, in 2009, examination of single versus combined
BP components and risk for CVD showed the following: 1)
Combined BP models [SBP þDBP or PP þ MAP] were
similar to each other in predicting risk, but they were
clearly superior to any single BP component in risk
prediction. 2) PP þ MAP had a monotonic relation in
predicting risk and, therefore, may give greater insight into
the hemodynamics of altered stiffness versus altered
peripheral resistance. 3) Only DBP had a quadratic relation
to CVD risk so that there was a DBP J-curve in predicting
CVD risk. 4) DBP <70 mm Hg in the presence of elevated
SBP is a powerful risk factor that is approximately equiv-
alent to a rise of 20 mm Hg in SBP. 5) Current JNC-7
guidelines consider the risk of elevated DBP, but they
ignore the increased risk of low DBP.
The original Framingham papers have helped pave the
way for the development of BP categories by both the
United States’ JNC and the European Society for Hyper-
tension. The greater risk conferred by increasing BP levels
in the presence of multiple risk factors, as shown originally
by Framingham, set the stage for the risk-based classiﬁca-
tion scheme recommended by the European Society for
Hypertension [11]. Both these classiﬁcations have been
crucial in the development of targets for initiation and
goals of BP treatment by these and other societies inter-
nationally. We believe our recent Framingham articles
[5e7] have set the stage for newer guidelines to place
a greater emphasis of PP, isolated systolic hypertension,
and low DBP in identifying patients at increased risk of
CVD. Perhaps most important, however, is that the Fra-
mingham Heart Study has raised awareness regarding
hypertension, now the leading cause of mortality globally,
for which renewed efforts to reduce sodium intake and
improvement in hypertension control are an important
focus of cardiovascular societies worldwide.GLOBAL HEART, VOL. 8, NO. 1, 2013
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